Literature DB >> 8264891

Successful treatment of recurrent malignant germ cell tumors: report of two cases.

M Matsutani1, A Asai, T Fujimaki, O Nakamura.   

Abstract

We report two patients with recurrent malignant germ cell tumors who were successfully treated with radiation therapy and cisplatin combination chemotherapy. Patient 1, who had a suprasellar mixed yolk sac tumor, had been free of tumor for 3.5 years after cisplatin/vinblastine/bleomycin combination chemotherapy alone but showed a recurrent tumor in the pineal region. In Patient 2, who had a pineal alpha-fetoprotein-producing tumor, recurrent tumors appeared in the lateral ventricle 3 years after the tumor was controlled by radiation and cisplatin/vinblastine/bleomycin therapy. They were treated successfully again by radiation therapy, followed by cisplatin and etoposide combination therapy, and they have been free of tumor for 5.5 and 7 years after recurrence, respectively. The total dose of cisplatin in both patients exceeded 1,000 mg/m2, which would have contributed to the control of the recurrent tumors. Anterior pituitary dysfunction observed in Patient 1 did not improve, even after tumor disappearance by chemotherapy, suggesting severe damage to the neurohypophysis by direct invasion of the tumor.

Entities:  

Mesh:

Year:  1993        PMID: 8264891     DOI: 10.1227/00006123-199311000-00020

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  2 in total

1.  An attempt to treat pediatric intracranial alphaFP and betaHCG secreting germ cell tumors with chemotherapy alone. SFOP experience with 18 cases. Société Française d'Oncologie Pédiatrique.

Authors:  M C Baranzelli; C Patte; E Bouffet; M Portas; F Mechinaud-Lacroix; E Sariban; H Roche; C Kalifa
Journal:  J Neurooncol       Date:  1998-05       Impact factor: 4.130

2.  CT and MRI features of intracranial germ cell tumors.

Authors:  T Fujimaki; M Matsutani; N Funada; T Kirino; K Takakura; O Nakamura; A Tamura; K Sano
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.